| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/07/2013 | US20130035290 Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury |
| 02/07/2013 | US20130035289 Pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (prl)-growth hormone (gh)-placental lactogen (pl)-family protein |
| 02/07/2013 | US20130035288 Resorption Enhancers As Additives To Improve The Oral Formulation Of Non-Anticoagulant Sulfated Polysaccharides |
| 02/07/2013 | US20130035287 Transient immortalization |
| 02/07/2013 | US20130035286 Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues |
| 02/07/2013 | US20130035285 Novel glucagon analogues |
| 02/07/2013 | US20130035284 Small-molecule inhibitors of dengue and west nile virus proteases |
| 02/07/2013 | US20130035283 Engineered opsonin for pathogen detection and treatment |
| 02/07/2013 | US20130035282 Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide |
| 02/07/2013 | US20130035281 Pharmaceutical composition, methods for treating and uses thereof |
| 02/07/2013 | US20130035280 Method and means for identifying substances which inhibit IgE production |
| 02/07/2013 | US20130035279 Method and a system for producing thermolabile nanoparticles with controlled properties and nanoparticles matrices made thereby |
| 02/07/2013 | US20130035260 Genes involved in inflammatory bowel diseases and use thereof |
| 02/07/2013 | US20130034611 Sustained preparation of factor ix |
| 02/07/2013 | US20130034610 Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| 02/07/2013 | US20130034602 Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery |
| 02/07/2013 | US20130034600 Peptide pharmaceutical of oral delivery |
| 02/07/2013 | US20130034598 Inhibitors of akt/pkb with anti-tumor activity |
| 02/07/2013 | US20130034597 Orally bioavailable peptide drug compositions and methods thereof |
| 02/07/2013 | US20130034596 Use of synthetic polysulphated oligosaccharides as cleaning agents for a wound |
| 02/07/2013 | US20130034590 Delivery of Hydrophilic Drugs |
| 02/07/2013 | US20130034589 pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY |
| 02/07/2013 | US20130034568 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 02/07/2013 | US20130034561 Isolated mammalian monocyte cell genes; related reagents |
| 02/07/2013 | US20130034547 Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
| 02/07/2013 | US20130034538 Reverse hexagonal mesophases (hii) and uses thereof |
| 02/07/2013 | US20130034536 Bile Acid Recycling Inhibitors for Treatment of Pancreatitis |
| 02/07/2013 | US20130034535 Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics |
| 02/07/2013 | US20130034534 Method for treatment of patients with cystic fibrosis |
| 02/07/2013 | US20130034533 High Molecular Weight Derivatives of Vitamin K-Dependent Polypeptides |
| 02/07/2013 | US20130034532 Nanozymes, methods of making nanozymes, and methods of using nanozymes |
| 02/07/2013 | US20130034531 Use of proteases for gluten intolerance |
| 02/07/2013 | US20130034530 Dietary Supplement Cognitive Support System |
| 02/07/2013 | US20130034529 Natural compositions and methods of promoting wound healing |
| 02/07/2013 | US20130034523 Use of sdf-1 to mitigate scar formation |
| 02/07/2013 | US20130034522 Therapies for treating hepatitis c virus infection |
| 02/07/2013 | US20130034521 1'-substituted carba-nucleoside analogs for antiviral treatment |
| 02/07/2013 | US20130034520 Hepatitis C Virus Inhibitors |
| 02/07/2013 | US20130034519 Organic compounds and their uses |
| 02/07/2013 | US20130034518 Interleukin-12 P40 Variants with Improved Stability |
| 02/07/2013 | DE102012018855A1 Insulin useful for lowering blood sugar in diabetic patients, comprises an active substance composition comprising animal cells and/or animal tissue parts containing animal insulin, which allows the oral insulin supply |
| 02/07/2013 | CA2843896A1 Collagen 7 and related methods |
| 02/07/2013 | CA2843794A1 Formulations containing saccharomyces boulardii and superoxide dismutase (sod) to control obesity |
| 02/07/2013 | CA2843672A1 Long-acting growth hormone and methods of producing same |
| 02/07/2013 | CA2843535A1 Treatment of heart failure and related conditions |
| 02/07/2013 | CA2843495A1 Hcv immunotherapy |
| 02/07/2013 | CA2843197A1 Purified proteins |
| 02/07/2013 | CA2842906A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | CA2842707A1 Bile acid recycling inhibitors for treatment of pancreatitis |
| 02/07/2013 | CA2842368A1 Switch costimulatory receptors |
| 02/07/2013 | CA2841933A1 Alteration of proteolytic cleavage of botulinum neurotoxins |
| 02/07/2013 | CA2839973A1 Procedure for obtaining a composition containing growth factors from a blood compound, and composition obtained by said procedure |
| 02/06/2013 | EP2554660A1 Intervertebral disc nucleus pulposus stem/progenitor cell, method for culturing same, and application |
| 02/06/2013 | EP2554550A1 Method for inhibiting hiv replication in mammal and human cells |
| 02/06/2013 | EP2554183A1 Pharmaceutical composition comprising a GLP-1-agonist, an insulin, and methionine |
| 02/06/2013 | EP2554182A1 Mammal sestrins in the treatment of muscle wasting |
| 02/06/2013 | EP2554181A2 Methods of protecting against apoptosis using lipopeptides |
| 02/06/2013 | EP2554180A1 Compounds for use in the treatment of diseases based on the expression of toxic transcripts |
| 02/06/2013 | EP2554175A1 Composition for treatment of damaged part |
| 02/06/2013 | EP2554161A1 Pharmaceutical composition comprising factor VII encapsulated in micelles |
| 02/06/2013 | EP2554160A1 Method for preparing an enriched IgG composition from plasma |
| 02/06/2013 | EP2553464A1 Fertilization prediction and promotion |
| 02/06/2013 | EP2553462A1 Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments |
| 02/06/2013 | EP2553101A2 Protease activated cytokines |
| 02/06/2013 | EP2552954A1 Factor xii inhibitors for treating interstitial lung disease |
| 02/06/2013 | EP2552952A1 Novel glucagon analogues |
| 02/06/2013 | EP2552951A1 Novel glucagon analogues |
| 02/06/2013 | EP2552950A1 Novel glucagon analogues |
| 02/06/2013 | EP2552947A2 Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| 02/06/2013 | EP2552944A1 Compositions and methods for the removal of biofilms |
| 02/06/2013 | EP2552940A2 Peptides for promoting angiogenesis and an use thereof |
| 02/06/2013 | EP2552939A1 Rfamide-related peptides and methods thereof |
| 02/06/2013 | EP2552938A1 Amphiphilic linear peptide/peptoid and hydrogel comprising the same |
| 02/06/2013 | EP2552475A1 Botulinum toxin dosage regimen for chronic migraine prophylaxis |
| 02/06/2013 | EP2552474A2 An insulin conjugate using an immunoglobulin fragment |
| 02/06/2013 | EP2552473A2 Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain |
| 02/06/2013 | EP2552472A2 Anti-inflammatory factors |
| 02/06/2013 | EP2552471A1 Novel peptides and methods for their preparation and use |
| 02/06/2013 | EP2552470A2 Peptides for promoting angiogenesis and an use thereof |
| 02/06/2013 | EP2552469A1 Methods for treating combined radiation and thermal injury |
| 02/06/2013 | EP2552468A1 Implant cannula having an implant and method for securing implants in an injection cannula |
| 02/06/2013 | EP2552463A1 Proangiogenic compositions, method for preparing same, and uses thereof |
| 02/06/2013 | EP2552462A2 Ccn3 peptides and analogs thereof for therapeutic use |
| 02/06/2013 | EP2552451A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 02/06/2013 | EP2552434A2 Peptides and their use |
| 02/06/2013 | EP2552422A2 Long-acting interferon beta formulation using immunoglobulin fragment |
| 02/06/2013 | EP2552418A2 A fast dissolving pharmaceutical composition |
| 02/06/2013 | EP2552407A1 Composition comprising insulin and herbal oil for transdermal or transmucosal administration |
| 02/06/2013 | EP2552403A2 A fast dissolving pharmaceutical composition |
| 02/06/2013 | EP2514761A9 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof |
| 02/06/2013 | CN1378445B Drug releasing biodegradable fiber implant |
| 02/06/2013 | CN102918056A Novel glucagon analogues |
| 02/06/2013 | CN102918055A Novel glucagon analogues |
| 02/06/2013 | CN102917728A Botulinum toxin dosage regimen for chronic migraine prophylaxis |
| 02/06/2013 | CN102917727A APOE peptide dimers and uses thereof |
| 02/06/2013 | CN102917726A Interferon analogs |
| 02/06/2013 | CN102917725A Cancer therapy method |
| 02/06/2013 | CN102917724A Pea protein peptides with anti helicobacter pylori activity |
| 02/06/2013 | CN102917723A Soybean protein hydrolysate-containing antioxidant and use thereof |
| 02/06/2013 | CN102917722A Aqueous formulations for coating microneedle arrays |